US OptionsDetailed Quotes
NVS240920P120000
- 3.20
- +0.10+3.23%
15min DelayClose Sep 9 16:00 ET
3.20High2.95Low
2.95Open3.10Pre Close2 Volume211 Open Interest120.00Strike Price615.00Turnover17.48%IV0.31%PremiumSep 20, 2024Expiry Date2.84Intrinsic Value100Multiplier10DDays to Expiry0.36Extrinsic Value100Contract SizeAmericanOptions Type-0.7839Delta0.0917Gamma37.19Leverage Ratio-0.0396Theta-0.0188Rho-29.16Eff Leverage0.0573Vega
Novartis AG Stock Discussion
Sign in to post a comment
Morning Movers
Gapping up
$Autodesk (ADSK.US)$ Shares rose by 0.8% following the software group's impressive second-quarter results, which were predominantly above consensus forecasts. The company's recent outlook upgrade also suggests strong business momentum.
$Tesla (TSLA.US)$ Shares increased by 1.2% as the electric vehicle manufacturer reported its best sales month of the year in China for August, driven by strong demand in s...
Gapping up
$Autodesk (ADSK.US)$ Shares rose by 0.8% following the software group's impressive second-quarter results, which were predominantly above consensus forecasts. The company's recent outlook upgrade also suggests strong business momentum.
$Tesla (TSLA.US)$ Shares increased by 1.2% as the electric vehicle manufacturer reported its best sales month of the year in China for August, driven by strong demand in s...
24
1
$Novartis AG (NVS.US)$
On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U...
On Monday, a Delaware court denied the Swiss pharma giant's attempt for a preliminary injunction to block MSN Pharmaceuticals from launching their generic version on the U.S. market. 2024 guidance doesn't currently account for any generic releases of its best-selling drug Entresto in the U.S., the analysts say. "Should a generic Entresto get to the U.S. market, it would put about 1.5 billion U...
The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...
The season started off last Friday with $JPMorgan (JPM.US)$ , $Wells Fargo & Co (WFC.US)$ , and $Wells Fargo & Co (WFC.US)$ sharing their numbers. They all did bett...
+3
25
Keep an eye on these recently announced M&As: 👀
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
$Merck & Co (MRK.US)$ to acquire EyeBio
$Biogen (BIIB.US)$ to acquire HI-Bio™
$Johnson & Johnson (JNJ.US)$ to acquire Proteologix
OnKure, Inc. merger with $Reneo Pharmaceuticals (RPHM.US)$
$Novartis AG (NVS.US)$ to acquire Mariana Oncology
What companies will be next? 🤔
6
$Esperion Therapeutics (ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
Stories you might have missed ![]()
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
Singapore’s private home sales down nearly half in February; 149 condos sold amid holiday lull
DEVELOPERS in Singapore sold 149 private homes in February, 47 per cent fewer than the 281 units moved in January, data released on Friday (Mar 15) by the Urban Redevelopment Authority showed.
Novartis invests US$256 million to expand Singapore plant
SWISS biopharma giant Novartis has invested US$256 million to expand its biopharm...
7
Google's disappointing ad sales growth and AMD's lower revenue guidance have hurt investor sentiment, causing their shares to drop. Byron Allen's offer to acquire Paramount Global is seen as beneficial for shareholders, boosting its share price. Novartis AG's lower Q4 earnings and adjusted mid-term guidance have led to a share price decline.
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
Recent M&A activities💰 in January:
$Ambrx Biopharma (AMAM.US)$ acquisition by $Johnson & Johnson (JNJ.US)$
Aiolos Bio acquisition by $GlaxoSmithKline (GSK.US)$
$Harpoon Therapeutics (HARP.US)$ acquisition by $Merck & Co (MRK.US)$
Calypso Biotech acquisition by $Novartis AG (NVS.US)$
What companies will be next? 🤔
$Ambrx Biopharma (AMAM.US)$ acquisition by $Johnson & Johnson (JNJ.US)$
Aiolos Bio acquisition by $GlaxoSmithKline (GSK.US)$
$Harpoon Therapeutics (HARP.US)$ acquisition by $Merck & Co (MRK.US)$
Calypso Biotech acquisition by $Novartis AG (NVS.US)$
What companies will be next? 🤔
1
Since last October, the biotech sector has been showing signs of recovery. This trend was underscored by the S&P Biotechnology Select Industry Index, which surged by 4.69% yesterday and jumped to a new high since Aug 2022.On 8 Jan, J&J, Merck, and Novartis each announced a series of acquisition deals, many of which featured premiums of over 100%:
● $Johnson & Johnson (JNJ.US)$ has agreed to pay $2 billion in cash for antib...
● $Johnson & Johnson (JNJ.US)$ has agreed to pay $2 billion in cash for antib...
10
No comment yet
Daprocessor : see 50%